Online ECHO Clinic | May 13, 2020
Presentation Title: Gender-Affirming Hormones for Adults and Adolescents
Dr. Robert Goldstein, Medical Director of the Transgender Health Program at Massachusetts General Hospital, explains the importance of obtaining consent before beginning hormone therapy and the variable timeline of physical change once hormone therapy has begun. Dr. Goldstein also provides a brief overview of the hormone regimens most commonly used for both transmen and transwomen and the associated risks of hormone therapy for all individuals.
Robert Goldstein, MD, PhD, (he/him/his) is an instructor at Harvard Medical School and serves as the Medical Director of the Transgender Health Program at Massachusetts General Hospital. Dr. Goldstein received his undergraduate degree, MD, and PhD at Tufts University before coming to MGH for his internship, residency, and chief residency. He completed the combined MGH/BWH Infectious Disease Fellowship in the HIV clinician educator track, and he joined the faculty in 2018 as an infectious disease physician and primary care provider in the Transgender Health Program. His clinical practice is focused on caring for the LGBTQ community, those living with HIV, and those at risk for HIV.